Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

@article{Herold2003ActivationOH,
  title={Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).},
  author={Kevan C Herold and Joshua B Burton and Fleur François and Ena Poumian-Ruiz and Mariela Glandt and Jeffrey A Bluestone},
  journal={The Journal of clinical investigation},
  year={2003},
  volume={111 3},
  pages={409-18}
}
Dimeric Fc receptor (FcR) nonbinding anti-CD3 antibodies have been developed to minimize toxicities associated with classical anti-CD3 monoclonal antibodies (e.g., OKT3). Studies with murine analogs of non-FcR-binding antibodies have shown reduced mitogenicity compared to OKT3. In a trial of an FcR nonbinding humanized anti-CD3 mAb hOKT3gamma1(Ala-Ala) for treatment of patients with type 1 diabetes, we found significant increases in IL-10 and IL-5 in the serum of 63% and 72% of patients… CONTINUE READING